Email Updates

Search form

You are here

HIV Prevention in the Era of PrEP: The implications of TDF/FTC for biomedical prevention trials

top

AVAC
Thursday, October 26, 2017

On Thursday, October 26, colleagues from the Treatment Action Group (TAG), along with advocates, researchers and GPP practitioners, discussed the recommendations from the TAG's recently released white paper, HIV Research in the Era of PrEP: The Implications of TDF/FTC for Biomedical Prevention Trials.

The effectiveness and increasing availability of oral PrEP raises questions about how it should be incorporated into clinical trial designs for next-generation HIV prevention options. This paper explores ethics, the scientific literature to date, and advocates’ views on the issue.

Recording: YouTube / Audio / Slides